Glycohemoglobin: A Primary Predictor of the Development or Reversal of Complications of Diabetes Mellitus

Abstract

Background: Diabetes mellitus is a major health problem worldwide with long-term micro- and macrovascular complications responsible for a majority of its morbidity and mortality. The development and progression of these complications relate strongly to glycemic control. Methods: We reviewed the literature extensively for studies that relate glycemic control to the development and progression of diabetic complications. We discuss the problems of standardizing glycohemoglobin measurements for monitoring diabetic therapy and also consider recently developed electrospray ionization mass spectrometry methods that have been considered as candidate reference methods for estimation of glycohemoglobin. Results: Several clinical trials and studies have clearly shown that improved glycemic control is strongly associated with decreased development and/or progression of complications in both type 1 and type 2 diabetes mellitus. Irrespective of the methods used for estimating glycohemoglobin, these results underline the importance of glycohemoglobin for guiding therapy of diabetes mellitus. Recently developed candidate reference methods promise to yield greatly improved standardization for the measurement of glycohemoglobin. Conclusions: Glycohemoglobin measurement remains the optimal indicator of glycemic control in diabetic patients, but translation of findings from clinical trials to clinical practice worldwide demands consistent values across all assays. To ensure that the important prognostic information still applies to all diabetic patients with the application of the reference method(s), the hemoglobin A1c values reported in the major clinical trials will have to be translated into statistically and computationally compatible values based on the new reference system(s).

The urinary proteome in diabetes and diabetes‐associated complications: New ways to assess disease progression and evaluate therapy

“…Because of their high reactivity, these compounds are suspected to play a role in the development and progression of late diabetic complications. Already in 2001, haemoglobin, albumin and myosin were described as glycated [34][35][36]. Ahmed et al [37] reported on an up to ten-fold increase in protein glycation and oxidation-free adducts in the blood of diabetic patients, and an up to 15-fold increase in urinary excretion.…”

Diabetic microvascular complications: can patients at risk be identified? A review

“…Prevention of complications specific to diabetes is a key issue because of the morbidity and mortality associated with the disease (4). Clinically significant morbidity may often develop before diagnosis (5).…”

Application of electron transfer dissociation mass spectrometry in analyses of non‐enzymatically glycated peptides

“…2 Glycated hemoglobin (HbA1c) has been used as a clinical diagnostic marker of relatively long-term ($90 days) glucose control in diabetic patients. 3 However, the Maillard reaction, and AGEs in general, are believed to play a more pathogenic role in the development of atherosclerosis and diabetic complications. The Maillard hypothesis of diabetic complications proposes that chronic, cumulative chemical modification of proteins by glycation and AGEs alters their turnover, structure, and function.…”